New insulin challenger takes on standard therapy for type 2 diabetes
NCT ID NCT07527078
First seen May 08, 2026 · Last updated Jun 16, 2026 · Updated 9 times
Summary
This study tests a new insulin called GZR33 against a standard insulin (Tresiba) in 350 adults with type 2 diabetes whose blood sugar is not well controlled by pills alone. The main goal is to see if GZR33 lowers blood sugar levels (HbA1c) as well or better after 26 weeks. Participants will receive injections and have their blood sugar and safety monitored.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES (T2DM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gan & Lee Pharmaceuticals
Beijing, China
Conditions
Explore the condition pages connected to this study.